TABLE 1. Estimated vaccination coverage by age 24 months,* among children born during 2016–2017 and during 2018–2019 for selected vaccines and doses — National Immunization Survey–Child, United States, 2017–2021.

Vaccine and dose	% (95% CI)
	Birth year†		Percentage point difference
	2016–2017	2018–2019	(2016–2017 to 2018–2019)
DTaP§
≥3 doses	93.2 (92.6 to 93.7)	94.2 (93.6 to 94.8)	1.0 (0.2 to 1.9)¶
≥4 doses	80.6 (79.7 to 81.6)	81.9 (80.9 to 82.8)	1.3 (−0.1 to 2.6)
Poliovirus (≥3 doses)	92.0 (91.4 to 92.6)	93.4 (92.8 to 94.0)	1.4 (0.5 to 2.2)¶
MMR (≥1 dose)**	90.6 (89.9 to 91.3)	91.6 (90.9 to 92.3)	1.1 (0.1 to 2.0)¶
Hib ††
Primary series	92.4 (91.7 to 93.0)	93.6 (93.0 to 94.1)	1.2 (0.3 to 2.1)¶
Full series	79.6 (78.6 to 80.6)	80.0 (79.0 to 81.0)	0.4 (−1.0 to 1.8)
HepB
Birth dose§§	76.4 (75.4 to 77.4)	79.8 (78.8 to 80.8)	3.4 (2.0 to 4.8)¶
≥3 doses	91.2 (90.6 to 91.9)	92.7 (92.0 to 93.3)	1.4 (0.5 to 2.3)¶
VAR (≥1 dose)**	90.1 (89.4 to 90.8)	91.1 (90.3 to 91.8)	1.0 (0 to 2.0)
PCV
≥3 doses	91.7 (91.0 to 92.3)	93.3 (92.7 to 93.9)	1.7 (0.8 to 2.5)¶
≥4 doses	81.2 (80.2 to 82.1)	83.5 (82.6 to 84.4)	2.3 (1.0 to 3.7)¶
HepA
≥1 dose	85.6 (84.8 to 86.4)	88.3 (87.5 to 89.1)	2.7 (1.5 to 3.8)¶
≥2 doses¶¶	45.2 (44.0 to 46.4)	47.3 (46.0 to 48.5)	2.1 (0.3 to 3.8)¶
≥2 doses (by age 35 mos)¶¶	76.8 (75.6 to 78.1)	79.6 (78.0 to 81.0)	2.7 (0.8 to 4.7)¶
Rotavirus (by age 8 mos)***	74.6 (73.5 to 75.6)	77.1 (76.1 to 78.2)	2.6 (1.1 to 4.1)¶
Influenza (≥2 doses)†††	57.5 (56.3 to 58.6)	63.9 (62.7 to 65.0)	6.4 (4.8 to 8.0)¶
Combined 7-vaccine series§§§	69.8 (68.6 to 70.9)	70.1 (68.9 to 71.2)	0.3 (−1.3 to 1.9)
No vaccinations¶¶¶	1.3 (1.1 to 1.5)	0.9 (0.7 to 1.1)	−0.4 (−0.7 to −0.1)¶

Abbreviations: DTaP = diphtheria, tetanus toxoids, and acellular pertussis vaccine; HepA = hepatitis A vaccine; HepB = hepatitis B vaccine; Hib = Haemophilus influenzae type b conjugate vaccine; MMR = measles, mumps, and rubella vaccine; PCV = pneumococcal conjugate vaccine; RV5 = pentavalent rotavirus vaccine; VAR = varicella vaccine.

* Includes vaccinations received by age 24 months (before the day the child turns age 24 months), except for the HepB birth dose, rotavirus vaccination, and ≥2 HepA doses by age 35 months. For all vaccines except the HepB birth dose and rotavirus vaccination, the Kaplan-Meier method was used to estimate vaccination coverage to account for children whose vaccination history was ascertained before age 24 months (age 35 months for ≥2 HepA doses).

^† Data for the 2016 birth year are from survey years 2017, 2018, and 2019; data for the 2017 birth year are from survey years 2018, 2019, and 2020; data for the 2018 birth year are from survey years 2019, 2020, and 2021; data for the 2019 birth year are considered preliminary and are from survey years 2020 and 2021 (data from survey year 2022 are not yet available).

^§ Includes children who might have received diphtheria and tetanus toxoids vaccine or diphtheria, tetanus toxoids, and pertussis vaccine. Healthy People 2030 target for ≥4 doses of DTaP is 90%. https://health.gov/healthypeople/objectives-and-data/browse-objectives/vaccination

^¶ Statistically significantly different from 0 at p<0.05.

** Includes children who might have received measles, mumps, rubella, and varicella combination vaccine. Healthy People 2030 target for ≥1 dose of MMR is 90.8%. https://health.gov/healthypeople/objectives-and-data/browse-objectives/vaccination

^†† Hib primary series: receipt of ≥2 or ≥3 doses, depending on product type received; full series: primary series and booster dose, which includes receipt of ≥3 or ≥4 doses, depending on product type received.

^§§ One dose HepB administered from birth through age 3 days.

^¶¶ Before 2020, first dose of HepA was recommended at age 12–23 months, with second dose administered 6–18 months after the first, depending upon the product type received. During 2020, recommendation was revised to 2 doses between ages 12 and 23 months, ≥6 months apart. Because children in this analysis were vaccinated under both recommendations, coverage estimates for both <24 months and <35 months are provided.

*** Includes ≥2 doses of Rotarix monovalent rotavirus vaccine or ≥3 doses of RotaTeq RV5. If any dose in the series is either RV5 or unknown, the default is a 3-dose series. The maximum age for the final rotavirus dose is age 8 months, 0 days.

^††† Doses must be ≥24 days apart (4 weeks with a 4-day grace period); doses could have been received during two influenza seasons.

^§§§ The combined 7-vaccine series (4:3:1:3*:3:1:4) includes ≥4 doses of DTaP, ≥3 doses of poliovirus vaccine, ≥1 dose of measles-containing vaccine, the full Hib series (≥3 or ≥4 doses, depending on product type), ≥3 doses of HepB, ≥1 dose of VAR, and ≥4 doses of PCV.

^¶¶¶ Healthy People 2030 target for children who get zero recommended vaccines by age 2 years is 1.3%. https://health.gov/healthypeople/objectives-and-data/browse-objectives/vaccination